Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Glioblastoma requiring standard care chemoradiation of concurrent Temozolomide and 60 Gy of radiation given over 30 treatments~* Age 21-70~* Able to give informed consent, and comply with study procedures~Exclusion Criteria:~* Meet DSM-V criteria for current major psychiatric illness, such as bipolar disorder, major depression, active suicidal intent, or psychosis that could be exacerbated by the administration of cannabis~* Meet DSM-V criteria for major neurological disorder, such as mild cognitive impairment or neurodegenerative disorders (such as movement disorders, dementia), that could be exacerbated by the administration of cannabis.~* Women who are not practicing an effective form of birth control (condoms, diaphragm, birth control pill, IUD) or currently pregnant.~* Current (weekly) use of cannabis.~* Patients on supplemental oxygen or history of chronic obstructive pulmonary disease (COPD).~* Cardiovascular Disease~* Compromised Immunity~* Patients with a history of substance use disorder other than nicotine, such an opiate use disorder.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cannabis + Chemoradiation (Type: EXPERIMENTAL): Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).